상세 보기
Major Depressive Disorder: Rethinking and Understanding Recent Discoveries
- Na, K.-S.;
- Kim, Y.-K.
초록
Major depressive disorder (MDD) shows a high prevalence and is associated with increased disability. While traditional studies aimed to investigate global characteristic neurobiological substrates of MDD, machine learning-based approaches focus on individual people rather than a group. Therefore, machine learning has been increasingly conducted and applied to clinical practice. Several previous neuroimaging studies used machine learning for stratifying MDD patients from healthy controls as well as in differentially diagnosing MDD apart from other psychiatric disorders. Also, machine learning has been used to predict treatment response using magnetic resonance imaging (MRI) results. Despite the recent accomplishments of machine learning-based MRI studies, small sample sizes and the heterogeneity of the depression group limit the generalizability of a machine learning-based predictive model. Future neuroimaging studies should integrate various materials such as genetic, peripheral, and clinical phenotypes for more accurate predictability of diagnosis and treatment response. © 2021, Springer Nature Singapore Pte Ltd.
- 제목
- Major Depressive Disorder: Rethinking and Understanding Recent Discoveries
- 저자
- Na, K.-S.; Kim, Y.-K.
- 발행일
- 2021-04
- ISBN
- 978-981-33-6043-3
- 언어
- ENG
- 출판사
- Kluwer Academic/Plenum Publishers
- 목차
- Part I Re-thinking Depression from a Network Perspective 1. Phenotype Network and Brain Structural Covariance Network of Major Depression - page 3 2. Task MRI-Based Functional Brain Network of Major Depression - page 19 3. White Matter-Based Structural Brain Network of Major Depression - page 35 4. The Application of a Machine Learning-Based Brain MRI Approach in Major Depression - page 57 5. Common Currency Between Experience and Brain Spatiotemporal Psychopathology of the Resting State in Depression - page 71 6. Development of Neuroimaging-Based Biomarkers in Major Depression - page 85 Part II Current Diagnostic and Neurobiological Issues 7. Challenges and Strategies for Current Classifications of Depressive Disorders Proposal for Future Diagnostic Standards - page 103 8. Epigenetics A Missing Link Between Early Life Stress and Depression - page 117 9. From Leaky Gut to Impaired Glia-Neuron Communication in Depression - page 129 10. Neurogenesis and Neuroplasticity in Major Depression Its Therapeutic Implication - page 157 11. A Load to Find Clinically Useful Biomarkers for Depression - page 175 12. Genetic Architecture of Depression Where Do We Stand Now - page 203 13. Pharmacogenetic Pharmacogenomic Tests for Treatment Prediction in Depression - page 231 14. The Role of Neurotrophic Factors in Pathophysiology of Major Depressive Disorder - page 257 Part III Current Specific Treatments for Depression 15. Clinical Application of Real-Time fMRI-Based Neurofeedback for Depression - page 275 16. Cognitive Behavioral Therapy and Mindfulness-Based Cognitive Therapy for Depressive Disorders - page 295 17. Acceptance and Commitment Therapy for Major Depressive Disorder Insights into a New Generation of Face-to-Face Treatment and Digital Self-Help Approaches - page 311 18. Current Updates on Newer Forms of Transcranial Magnetic Stimulation in Major Depression - page 333 19. Well-being Therapy in Depressive Disorders - page 351 20. Current Research on Complementary and Alternative Medicine CAM in the Treatment of Major Depressive Disorder An Evidence-Based Review - page 375 21. Psychopharmacology Algorithms for Major Depressive Disorder Current Status - page 429 Part IV Promising Future Treatments for Depression 22. Novel Psychopharmacology for Depressive Disorders - page 449 23. Creative Person-Centered Narrative Psychopharmacotherapy of Depression - page 463 24. Induced Pluripotent Stem Cells iPSCs Technology Potential Targets for Depression - page 493 25. Vaccination and Immunotherapy for Major Depression - page 503 26. Psychedelic Medicines in Major Depression Progress and Future Challenges - page 515 27. Precision Psychiatry Biomarker-Guided Tailored Therapy for Effective Treatment and Prevention in Major Depression - page 535